Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway

Nature Immunology

Volumn 5, Issue 4, 2004, Pages 388-392

  Karp, Christopher L ^a   Flick, Leah M ^a   Park, Kiwon W ^b   Softic, Samir ^a   Greer, Todd M ^a   Keledjian, Raquel ^c   Yang, Rong ^c   Uddin, Jasmin ^c   Guggino, William B ^b   Atabani, Sowsan F ^a   Belkaid, Yasmine ^a   Xu, Yan ^a   Whitsett, Jeffrey A ^a   Accurso, Frank J ^d   Wills Karp, Marsha ^a   Petasis, Nicos A ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; LIPID; LIPOXIN; LIPOXIN A;

ADOLESCENT; ADULT; AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOSOMAL DISORDER; BODY BURDEN; CHILD; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG METABOLISM; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LUNG INFECTION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STATISTICAL SIGNIFICANCE;

CYSTIC FIBROSIS; EPITHELIUM; HUMANS; INFLAMMATION; LIPOXINS; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS;

EID: 4644272735     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni1056     Document Type: Article

References (38)

1. Welch, W.J., Ramsey, B.W., Accurso, F.J. & Cutting, G.R. in Metabolic and Molecular Bases of Inherited Disease (eds. Scriver, C.R. et al.) 521-588 (McGraw-Hill, New York, 2001).
2. Verkman, A.S., Song, Y. & Thiagarajah, J.R. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am. J. Physiol. Cell Physiol. 284, C2-C15 (2003).
3. Khan, T.Z. et al. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151, 1075-1082 (1995).
4. Bonfield, T.L. et al. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 152, 2111-2118 (1995).
5. Muhlebach, M.S., Stewart, P.W., Leigh, M.W. & Noah, T.L. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am. J. Respir. Crit. Care Med. 160, 186-191 (1999).
6. Noah, T.L., Black, H.R., Cheng, P.W., Wood, R.E. & Leigh, M.W. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J. Infect. Dis. 175, 638-647 (1997).
7. Tirouvanziam, R. et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am. J. Respir. Cell Mol. Biol. 23, 121-127 (2000).
8. Muhlebach, M.S. & Noah, T.L. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 165, 911-915 (2002).
9. 4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am. Rev. Respir. Dis. 148, 896-901 (1993).
10. McElvaney, N.G. et al. Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 337, 392-394 (1991).
11. Rosenberg, H.F. & Gallin, J.I. in Fundamental Immunology 4th edn. (ed. Paul, W.E.) 1051-1066 (Lippincott-Raven, Philadelphia, 1999).
12. Serhan, C.N. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat. 69, 433-455 (2002).
13. Fierro, I.M. & Serhan, C.N. Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Braz. J. Med. Biol. Res. 34, 555-566 (2001).
14. 4 analogs. J. Clin. Invest. 101, 1860-1869 (1998).
15. Clish, C.B. et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. USA 96, 8247-8252 (1999).
16. van Heeckeren, A.M. & Schluchter, M.D. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim. 36, 291-312 (2002).
17. Costerton, J.W. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol. 9, 50-52 (2001).
18. Stotland, P.K., Radzioch, D. & Stevenson, M.M. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis. Pediatr. Pulmonol. 30, 413-424 (2000).
19. Bonnans, C. et al. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit. Care Med. 165, 1531-1535 (2002).
20. Sanak, M. et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16, 44-49 (2000).
21. Hopen, U.E., Lu, B., Gerard, N.P. & Gerard, C. The C5a chemoattractant receptor mediates mucosal defense to infection. Nature 383, 25-26 (1996).
22. 2+ increase in human bronchial epithelium. J. Biol. Chem. 278, 10879-10884 (2003).
23. Pilewski, J.M. & Frizzell, R.A. Role of CFTR in airway disease. Physiol. Rev. 79, S215-S255 (1999).
24. Serhan, C.N., Levy, B.D., Clish, C.B., Gronert, K. & Chiang, N. Lipoxins, aspirin triggered 15-epi-lipoxin stable analogs and their receptors in anti-inflammation: a window for therapeutic opportunity. Ernst Schering Res. Found. Workshop 31, 143-185 (2000).
25. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K. & Serhan, C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612-619 (2001).
26. Xu, Y. et al. Transcriptional adaptation to cystic fibrosis transmembrane conductance regulator deficiency. J. Biol. Chem. 278, 7674-7682 (2003).
27. Hong, S., Gronert, K., Devchand, P.R., Moussignac, R.L. & Serhan, C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687 (2003).
28. Serhan, C.N. et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204 (2000).
29. Serhan, C.N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
30. Freedman, S.D., Shea, J.C., Blanco, P.G. & Alvarez, J.G. Fatty acids in cystic fibrosis. Curr. Opin. Pulm. Med. 6, 530-532 (2000).
31. Freedman, S.D. et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350, 560-569 (2004).
32. Gronert, K., Gewirtz, A., Madara, J.L. & Serhan, C.N. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon γ and inhibits tumor necrosis factor α-induced IL-8 release. J. Exp. Med. 187, 1285-1294 (1998).
33. 4 and regulation of vascular and inflammatory responses. Am. J. Pathol. 158, 3-9 (2001).
34. Sarau, H.M. et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol. Pharmacol. 56, 657-663 (1999).
35. Lynch, K.R. et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399, 789-793 (1999).
36. Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258-2261 (1998).
37. 4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168, 5260-5267 (2002).
38. Andrews, P.C. & Krinsky, N.L. Quantitative determination of myeloperoxidase using tetramethylbenzidine as substrate. Anal. Biochem. 127, 346-350 (1982).